Bupropion

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Zyban)

Bupropion is an atypical antidepressant medication sold under the brand names include Wellbutrin, Aplenzin, and Zyban, and formerly Budeprion.[1][2][3] In addition to treating depression and severe pain, it is also used to treat seasonal affective disorder (SAD), and to reduce cravings in smoking cessation and drug addiction.[1][4]

Types[edit | edit source]

Bupropion is available in different forms, and may be combined with other drugs for particular uses, including

  • Bupropion for smoking cessation, brand name Zyban
  • Bupropion for major depression, brand name Wellbutrin[4]

Theory[edit | edit source]

Buproprion, like all antidepressants, does not address the underlying mechanisms of ME/CFS, so should not be regarded as a cure. It should be used only to reduce particular symptoms or treat a co-existing disorder (e.g. depression), and it is not a primary treatment for ME/CFS.[5]

ME/CFS patients may tolerate brand name bupropion better than generic versions due to sensitivities.[citation needed]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 "Bupropion: MedlinePlus Drug Information". medlineplus.gov. Retrieved January 8, 2019.
  2. Cite error: Invalid <ref> tag; no text was provided for refs named PMC2729622
  3. Cite error: Invalid <ref> tag; no text was provided for refs named patch
  4. 4.0 4.1 https://www.drugs.com/bupropion
  5. Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, AC Peter; Sherkey, Jeffrey A.; van de Sande, Marjorie I. (2003), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols" (PDF), Journal of Chronic Fatigue Syndrome, 11 (2): 7–115, doi:10.1300/J092v11n01_02